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Abstract: Recent literature is reviewed about treatment of chronic hepatitis B virus (CHB), 
focusing on tenofovir disoproxil fumarate (TDF; Viread®), among the nucleotide and nucleoside 
analogs. TDF pharmacokinetics and pharmacodynamics, activity in respect of hepatitis B virus 
(HBV) multi-drug-resistant mutations, efﬁ  cacy in treatment-naïve and treatment-experienced 
patients, and side effects are described. The most predictive response factors to TDF therapy are 
discussed and all available combination therapies to optimize clinical outcome in the various 
patient proﬁ  les are analyzed, such as compensated and/or decompensated cirrhotic patients. The 
use of TDF in pregnancy, and prophylaxis after exposure to HBV and post-liver transplantation 
are also evaluated.
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Introduction
Hepatitis B virus (HBV) is a hepadnavirus (DNA virus) transmitted percutaneously, 
sexually and perinatally; despite the impressive impact of vaccination it remains a 
global health problem that affects 350 to 400 million persons worldwide.1,2
It is estimated that hepatitis B ranks third among the causes of liver-related death 
annually in Italy. The burden of HBV infection in Italy has recently been further 
increased by a massive inﬂ  ux of immigrants from Europe, Africa and Asia.3
HBV integrates into the host cell genome, with the primary targets being hepatic 
cells; although HBV is not a retrovirus, it relies on a retroviral strategy of reverse 
transcription from pregenomic RNA to negative-strand DNA. It establishes covalently 
closed circular DNA (cccDNA) as a durable and stable miniature chromosome in the 
host nucleus. Like retroviruses, it is susceptible to nucleoside reverse transcriptase 
inhibitors (nRTIs) and nucleotide reverse transcriptase inhibitors (ntRTIs). HBV can 
develop mutations that confer resistance.1,4
Genotypic resistance is universally deﬁ  ned by the detection of viral populations 
bearing amino acid substitutions in the reverse transcriptase region of the HBV genome 
that confer resistance to antiviral drugs.5
HBV infection is a complex and heterogeneous disease that can evolve in a variety 
of ways, including severe liver disease: cirrhosis with portal hypertension, liver failure 
and hepatocellular carcinoma (HCC).2
The end points of therapy in chronic hepatitis B virus (CHB) are:
•  serologic: hepatitis B e antigen (HBeAg) loss or seroconversion, usually reﬂ  ecting 
a transition to inactive HBV carriage and, more rarely, hepatitis B surface antigen 
(HBsAg) loss or seroconversion, representing serologic recovery;
•  virological: suppression of HBV DNA to an undetectable level or reduction in the 
HBV DNA level (at least 1–2 log10);
•  biochemical: normalization of the serum alanine aminotransferase (ALT) level;
•  histological: improvement in the necroinﬂ  ammatory grade and stage of ﬁ  brosis.1,6Therapeutics and Clinical Risk Management 2009:5 178
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The HBeAg status distinguishes two categories of chronic 
HBV infection. HBeAg-reactive chronic HBV infection is 
accompanied by high-level HBV replication, and spontaneous 
seroconversion from HBeAg-positive to hepatitis B e antibody 
(HBeAb)-positive infection coincides with a reduction in 
HBV replication and clinical improvement. HBeAg-negative 
chronic HBV infection, in which precore or core-promoter 
gene mutations preclude or reduce the synthesis of HBeAg, 
accounts for an increasing proportion of cases. Patients 
with HBeAg-negative chronic HBV infection tend to have 
progressive liver injury, ﬂ  uctuating ALT activity, and lower 
levels of HBV DNA than patients with HBeAg-reactive HBV 
infection; however, they cannot have treatment-induced 
HBeAg seroconversion, a durable response that may permit 
the discontinuation of antiviral therapy.
Eight HBV genotypes and differences in clinical outcomes 
to genotype are recognized. These differences, however, are 
not sufﬁ  ciently established to guide management.
Successful antiviral therapy retards hepatic ﬁ  brosis, and 
even reverses cirrhosis and improves survival.1
The number of medications to treat CHB continues to 
increase. Since 1990 many treatment options have been avail-
able: interferon (IFN) α2a and α2b, lamivudine (3TC/LAM), 
adefovir dipivoxil (ADV), entecavir, pegylated IFN α2a 
(PEG-IFN), telbivudine, and more recently tenofovir diso-
proxil fumarate (TDF; Viread®, Gilead Sciences, Foster City, 
California, USA), which was licensed by the Food and Drug 
Administration in August 2008.2,5
IFN-α therapy for 3 to 6 months is associated with loss 
of HBV DNA and HBeAg in 37% and 33% of patients, 
respectively. However, IFN-α is expensive and may be 
accompanied by frequent and unpleasant side effects.7 In 
HBeAg-negative patients, HBV DNA suppression is sustained 
after IFN therapy in a minority of patients and degrades 
gradually over time.1
Treatment of HBV with LAM for HBeAg-positive 
chronic hepatitis shows similar results. This treatment may 
not completely suppress viral replication and often fails as 
a result of LAM resistance associated with the appearance 
of the substitution of methionine within the tyrosine-
methionine-aspartate-aspartate (YMDD) and other mutations 
at the domain C of reverse transcriptase.1,7,8
LAM treatment may be successful but resistance develops 
at the rate of 10% a year (20% a year for HIV-positive 
patients). LAM resistance is also successful for a while in 
HBeAg-positive patients.5,6
Nucleotide and nucleoside analogs are effective in 
patients who previously did not respond to IFN, with 
contra-indications to PEG-IFN and/or non-responders to 
this therapy; they can be used safely and effectively as 
salvage therapy in patients with hepatic decompensation 
(delaying or averting liver transplantation), and may prevent 
hepatic decompensation in patients with advanced ﬁ  brosis 
and cirrhosis. Often this kind of strategy is used for a long 
period, even indeﬁ  nitely, which is justiﬁ  ed because of the 
possibility of ﬂ  ares after treatment withdrawal, the better 
histological response associated with longer suppression of 
HBV DNA, and the low chance of a sustained, post-treatment 
response.1,9
The aim of this review is to deﬁ  ne the role of TDF in 
CHB therapy, with a focus on recent guidelines.
Methodology
Literature on TDF and CHB treatment was reviewed. The 
pertinent literature was obtained by research including the 
most recent articles and PubMed of the last 8 years. The 
following keywords were used: hepatitis B virus, chronic 
hepatitis B, tenofovir, antiviral therapy, interferon, liver 
disease. Abstracts presented at major international congresses 
on viral hepatitis were also reviewed.
Tenofovir and its activity 
against HBV
TDF is an acyclic nucleotide analog, reverse transcriptase 
inhibitor. As ADV, its congener, it possess a phosphonate 
group attached to an acyclic nucleotide moiety through a 
stable P-C bond.10
With this conﬁ  guration it bypasses the ﬁ  rst phosphorylation 
kinase step that is needed to activate various nucleoside 
analogs2: it needs just two, instead of three, phosphorylation 
steps to reach the active metabolite stage. Therefore, it does 
not depend on the virus-induced kinase to exert its antiviral 
action and may be expected to have selective activity against 
a broad range of DNA virus, including hepadnaviruses 
(as HBV) and retroviruses (as human immunodeﬁ  ciency 
virus, HIV).10
TDF, diphosphorylated, competes with natural triphos-
phate deoxynucleosides for binding to the active site of HBV 
polymerase, and its incorporation at the end of the growing 
DNA terminates chain elongation. Furthermore TDF has a 
higher afﬁ  nity for the viral DNA polymerases than for human 
cellular DNA polymerases α, β, γ, δ and ε.
According to this mechanism, TDF minimally interferes 
with human nuclear DNA synthesis, and this may at least 
partially explain its low cytotoxicity and favorable safety 
proﬁ  le.10Therapeutics and Clinical Risk Management 2009:5 179
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TDF is currently approved for therapeutic use as the 
bis-alkoxyester prodrug tenofovir disoproxil fumarate. TDF 
is orally bioavailable, and the promoieties are cleaved during 
absorption to release it into systemic circulation.11
In 2001, TDF was licensed for HIV therapy because it is 
a potent inhibitor of HIV replication, but also it has proved 
a potent and selective anti-HBV agent in vitro.2
Clinical studies then conﬁ  rmed the efﬁ  cacy of TDF in 
suppressing HBV replication. Most of the studies, based 
on retrospective analysis of small subsets of HIV/HBV 
coinfected patients who received TDF primarily for HIV 
infection, demonstrated its excellent activity against HBV 
in both LAM-naïve and LAM-resistant patients.12–15
Activity of TDF has also been observed in different series 
of patients with HBV monoinfection.12
In several studies on HBV-infected patients, the vast 
majority with LAM-resistant virus, TDF 300 mg once 
daily resulted in a reduction of 4 to 6 log10 copies/mL in 
serum HBV DNA level from baseline over 48 weeks and in 
reduction of 5 log10 copies/mL compared with placebo; also 
HBV DNA was undetectable by PCR assay in 30% to 100% 
of patients after more than 24 weeks treatment.4,6,12
TDF, at a dose of 300 mg, is tolerated and more potent than 
ADV in achieving viral suppression deﬁ  ned as  400 copies/mL 
(76% vs 13%), histological improvement (67% vs 12%), 
and higher rates of HBsAg loss (3.2% vs 0%) at 48 weeks 
in patients with HBeAg-positive and HBeAg-negative 
CHB.5,16,17
In the study of Heathcote et al all eligible HBeAg-positive 
subjects were randomized to receive TDF (N = 176) or ADV 
(N = 90) for the ﬁ  rst 48 weeks; after 48 weeks they were 
either continued on TDF or switched from ADV to TDF 
for an additional 4 years.18 Recent 72-week data demon-
strate that 79% of patients who were originally randomized 
to receive TDF (vs 76% of switched patients) had  400 
copies/mL HBV DNA, 26% (vs 21% of switched patients) 
had HBeAg seroconversion and 5% (vs 0% of switched 
patients) had HBsAg loss. Additionally, the switch to TDF 
after 48 weeks of ADV therapy produced signiﬁ  cant addi-
tional viral suppression in 78% of patients with HBV DNA 
levels above 400 copies/mL.5,18
The same study with HBeAg-negative patients obtained 
similar results: 91% of patients who were originally 
randomized to receive TDF (vs 88% of switched patients) 
had HBV DNA   400 copies/mL. Similarly the switch to 
TDF after 48 weeks of ADV therapy produced signiﬁ  cant 
additional viral suppression in 94% of patients with HBV 
DNA levels above 400 copies/mL.5,19
Both ADV and TDF were well tolerated, with no evidence 
of signiﬁ  cant renal toxicity. Resistance surveillance through 
week 72 did not detect any TDF-associated mutation.5,18,19
van Bömmel et al described 20 patients with chronic HBV 
infection who suffered a virological breakthrough (deﬁ  ned 
as a  1 log10 increase in serum HBV DNA above nadir 
on 2 or more occasions after 1 month of therapy) during 
LAM therapy. This therapy was followed by an incomplete 
virological response (deﬁ  ned as a reduction in HBV DNA 
of less than 1 log copies/mL, a persistently high level of 
HBV replication, greater than 106 copies/mL after 4 months, 
or a HBV DNA level still greater than 105 copies/mL after 
12 months of ADV treatment) to ADV with persistently high 
viral replication. These patients showed a rapid virological 
response with TDF dosage of 300 mg/day. The presence of 
YMDD had no inﬂ  uence on TDF efﬁ  cacy.20,21
Differences between TDF and ADV in intracellular 
phosphorylation kinetics and possibly immunoregulatory 
mechanisms should also be considered as responsible for 
the observed differences in the antiviral effects of the two 
drugs.
These results raise questions about the role of TDF 
in clearing both the replicating forms in the hepatocyte 
cytoplasm and the HBV cccDNA inside the nucleus, and also 
the possible correlation between HBV cccDNA levels and 
changes in aminotransferase levels or histology.
Further studies are necessary to assess the superiority of 
TDF over ADV in suppressing HBV replication in patients 
with LAM-resistant mutations.21
Tan et al described 5 patients with a virological break-
through during ADV treatment in the absence of known 
ADV-resistant mutations, and 4 patients with a suboptimal 
virological response to ADV. Of these 9 patients, who were 
switched to TDF monotherapy, 2 had a suboptimal response 
while 7 had rapid virological response with undetectable 
serum HBV DNA within 3 to 15 months.20,22
Lada et al showed, in vitro, the excellent efﬁ  cacy of 
TDF on LAM-resistant virus independently of the resistance 
mutation proﬁ  le.22,23
In the study of van Bömmel et al limited to 3 patients 
with ADV-resistant HBV infection, although TDF mono-
therapy had signiﬁ  cant antiviral efﬁ  cacy in patients with 
ADV resistance, it could not induce complete suppression 
of HBV DNA in any of the three patients studied or 
prevent further selection of ADV-associated resistance 
mutations.22,24
These in vivo observations conﬁ  rm in vitro data that 
TDF has decreased antiviral activity against ADV-resistant Therapeutics and Clinical Risk Management 2009:5 180
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HBV compared to wild type virus, indicating the potential 
for cross-resistance.11,22
In terms of antiviral activity against multi-drug-resistance 
mutations, in vitro analysis indicates that TDF is far superior 
to the combination of LAM and ADV, and has a marginal 
beneﬁ  t over entecavir.25
The dose of 300 mg was chosen because ﬁ  rst studies were 
conducted in HBV/HIV coinfected patients with a dosage 
active against HIV; ADV is approved for the treatment of 
CHB at the dosage of 10 mg/day.
Many authors consider this difference in the dosage 
between TDF and ADV as primarily responsible for the 
failure of ADV to confer a sustained virological response.
Published data report the possible susceptibility of 
HBV to lower dosage of TDF (75 mg/day). In a 2007 study 
11 patients were treated with TDF 75 mg/day for a median 
period of 80 weeks and then 7 cases were shifted to an ADV 
10 mg/day treatment group. All patients had been pre-treated 
with LAM: 5 had YMDD-resistant mutants and 6 wild-
type virus. When TDF was started 4 patients had low-level 
viremia and 6 were PCR-negative. During TDF treatment, 
PCR remained negative in 10 patients. When TDF 75 mg was 
substituted with ADV 10 mg, 3 of 7 patients had a persistent 
viral rebound. The use of a reduced dose of TDF could have 
several practical implications, such as a lower cost of therapy, 
treatment of patients suffering from advanced stage CHB with 
a borderline renal function. Further studies are necessary.26
In terms of liver disease status, the rapid and strong 
antiviral efﬁ  cacy of TDF makes it an attractive rescue therapy 
for patients with liver cirrhosis.27
Choe et al studied a group of 6 patients afﬂ  icted with 
HBV-related cirrhosis with resistance or non-response to 
ADV. These patients underwent TDF/LAM combination 
therapy for at least 6 months: HBV DNA levels became 
undetectable in all patients, ALT levels were normalized 
in 4 patients and the Child-Pugh scores improved in 2 of 
3 patients with decompensation. The authors suggested that 
TDF plus LAM may be a promising rescue therapy in this 
kind of subject.28
Two reports of 6 and 7 HIV/HBV LAM-resistant 
coinfected decompensated cirrhotic patients, respectively, 
have also been published, supporting evidence for the role of 
TDF in the management of these cases. Marked clinical and 
laboratory improvement was shown in liver function (HBV 
viral suppression, HBeAg seroconversion, signiﬁ  cant changes 
in albumin, prothrombin, ALT and bilirubin levels).29,30
Furthermore, a recently published study by Buti et al 
demonstrated that TDF has good efﬁ  cacy and tolerability 
compared with ADV in subjects with compensated cirrhosis 
due to HBV.31
Predictors of response: genotype, 
ALT level and ﬁ  brosis
As a possible predicting factor for TDF therapy, HBV 
genotype may be considered. Different studies conﬁ  rmed that 
genotype A has better response to therapy. Genotype A would 
favor HBeAg seroconversion independent of type of therapy. 
Stephan et al showed a 50% response rate in HBV/HIV 
patients coinfected with HBV genotype A vs a 19% response 
rate in patients with non-A genotypes, who received a year 
of TDF-based antiretroviral therapy regimen. Also Jain et al 
demonstrate that infection with genotypes G, A/G, F and D 
is signiﬁ  cantly associated with non-response.1,32,33
In contrast, Lacombe et al concluded in their study that 
baseline HBV genomics such as genotype did not inﬂ  uence 
HBV decay; similar results had been reported previously 
with LAM and ADV.14,34,35
Stephan et al showed that patients with high-replicative 
virus may benefit from TDF therapy with a reduction 
in replicative status while subjects with low-level HBV 
replication who become undetectable HBV DNA and HBsAg 
carriers remain DNA negative.33
Elevated ALT levels at baseline were also associated with 
a more rapid HBV decay, whereas a METAVIR ﬁ  brosis score 
above 2 was associated with slower HBV decay. This result 
suggests that TDF is more efﬁ  cient in patients with active 
inﬂ  ammatory disease.14
Clearance of HBV by TDF
van der Eijk et al studied viral dynamics in the course of TDF 
therapy in patients with LAM-resistant HBV mutants.
The effect of antiviral therapy was evaluated by 
mathematical modeling: a biphasic clearance of HBV DNA 
has been demonstrated with an initial fast phase of viral 
load decline reﬂ  ecting the clearance of HBV particles from 
plasma with a half-life of approximately 24 hours, followed 
by a second slower phase of viral load decline, mirroring the 
rate-limiting process of the loss of infected cells.36,37
The duration of the ﬁ  rst phase is  7 days, which means 
that the transition from the ﬁ  rst to the second phase occurs 
in the ﬁ  rst week.37
The death of these cells requires a cellular immune 
response by the host. In HBV monoinfection a possible 
marker of the strength of host immune response is the level 
of ALT, which is an indicator of the level of cell damage 
and death.37,38Therapeutics and Clinical Risk Management 2009:5 181
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van der Eijk et al concluded in their 2005 study that 
analysis of these viral kinetics can be used to calculate both the 
effectiveness of therapy in inhibiting viral production as well as 
the clearance of cells infected with HBV. They also described 
that after 4 weeks, treatment response was less predictable and 
a variety of patterns of viral decay was observed.
The authors also showed that TDF is capable of blocking 
viral replication with an efficacy of 0.99 in both HBV 
and HBV/HIV coinfected patients with LAM-induced 
drug-resistant mutants, so that some low-grade viral 
replication remains and may present a risk for development 
of mutation resistance during TDF therapy.37
Although the majority of patients experience a signiﬁ  cant 
reduction in HBV DNA levels and a normalization of 
serum ALT levels, an even smaller percentage of patients 
seroconverts to HBeAb, and thus far seroconversion of HBsAg 
to hepatitis B surface antibody (HBsAb) is rare. The use of 
combination chemotherapy, or especially immunomodulators, 
which shape cytotoxic or regulatory cells of the innate and 
adaptative immune system during the initial period of virus 
infection, should accelerate the loss of HBV DNA.39
HIV/HBV coinfection and TDF
The in vivo antiviral activity of TDF appears to be similar 
among patients with and without HIV coinfection.12
TDF is an ideal drug to treat HBV/HIV coinfected 
patients.
Also, the anti-HIV activity of TDF, which ADV lacks, 
and its excellent tolerability in patients with advanced HIV 
infection, make it more attractive for patients with limited 
therapeutic options in which the goal of antiretroviral therapy 
is not necessarily to reach HIV undetectability, but to try to 
lower the RNA load as much as possible.7,8
In coinfected HBV/HIV patients indicated for antiretroviral 
therapy, regimens should include TDF in association 
with LAM or emtricitabine (FTC); in patients who have 
developed LAM- or FTC-resistant HBV, addition of TDF 
to antiretroviral regimen including maintenance of LAM or 
FTC is the preferred choice.40
Tenofovir resistance
Typically, genotypic resistance is followed after some variable 
time interval by virological breakthrough, followed later by 
biochemical breakthrough (deﬁ  ned as a rise in ALT levels 
after achieving normalization while continuing to receive 
therapy) and possible clinical symptoms (signiﬁ  cant changes 
in prothrombin, ALT and bilirubin levels), sometimes called 
clinical breakthrough.
Recently published data suggest that monotherapy, long 
duration of therapy and inappropriate use of antiviral drug 
are the most important risk factors for emergence of viral 
resistance.5
The nucleotide analogs (ADV and TDF) are associated 
with mutations in polymerase domains B and D.1
Although LAM resistance is sufﬁ  ciently high to limit its 
clinical impact, resistance to entecavir and TDF remains low.1
Despite advances in HBV genotypic resistance testing, 
not all mutations can be detected at present. Therefore, 
genotypic testing cannot be recommended prior to initiation 
of therapy. Instead, patients receiving monotherapy need 
frequent monitoring (every 3–6 months) for emergence of 
resistance by checking serum HBV DNA.5
Once a patient develops virological breakthrough, 
resistance testing is paramount in identifying mutations and 
guiding the choice of a different agent.5
Patients with LAM resistance can be successfully 
treated by adding or switching to ADV, or by switching 
to entecavir, resulting in viral suppression, normalization 
of ALT levels and histological improvement. The current 
guidelines recommend adding a second drug rather than 
switching to a nucleotide agent to minimize the subsequent 
development of resistance to the new agent. Furthermore, 
a second drug added should be not cross-resistant with the 
ﬁ  rst drug.5
Combination therapy is not recommended except for 
patients in whom drug resistance can precipitate or aggravate 
hepatic failure, as in decompensated cirrhosis or after liver 
transplantation.1
Combination therapy with agents with differing resis-
tance proﬁ  les should limit the emergence of resistance; 
however, resistance is so negligible during early treatment 
with entecavir or TDF that demonstrating the superiority of 
pre-emptive combination therapy over initial monotherapy 
will be challenging.1
TDF represents an optimal choice for treatment-
experienced patients, especially those with LAM resistance; 
however, patients with previous therapy with ADV and 
the presence of ADV-resistance mutations have an inferior 
response to TDF.5
van Bömmel et al reported the results of a retrospective 
analysis of a cohort of 127 patients (all HBV monoinfected) 
from 15 centers in Germany and the Netherlands. They had been 
treated with TDF between 2002 and 2006: 6 were treatment 
naïve and 121 were treatment experienced (16 LAM, 9 ADV, 
72 sequential LAM and ADV, 21 add-on combination LAM 
and ADV, 2 entecavir and 1 sequential LAM and entecavir).Therapeutics and Clinical Risk Management 2009:5 182
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At month 12, 85% of patients had undetectable HBV DNA. 
Virological breakthrough was not observed. Baseline char-
acteristics such as age, sex, liver cirrhosis, as well as HBeAg 
status or LAM resistance, showed no inﬂ  uence on response 
to TDF. The rates of undetectable serum HBV DNA after 
12 months of TDF were 100% in those with no mutations, 
92% in those with YMDD mutations and only 30% in those 
with ADV-resistance mutations.5,41
A previous study by van Bömmel on 10 HBV monoinfected 
patients concluded that although TDF shows signiﬁ  cant 
antiviral efﬁ  cacy in patients with genotypic ADV resistance, 
undetectable HBV DNA is only achieved in a minority of the 
patients. Furthermore, ADV-resistance-associated mutations 
persisted during TDF treatment and required combination 
therapy with TDF or ADV plus LAM or entecavir.42
TDF had previously demonstrated full activity against 
LAM-resistant HBV (YMDD, rtL180M, rtM204V) in vitro 
and clinically.11,25
Since 2005 many authors have shown in vitro that ADV-
resistance mutations (rtN236T, rtA194T, rtA181V) did not 
cause a signiﬁ  cant change in TDF susceptibility, supporting 
its development for the treatment of CHB.11,18,20,25,43,44
These data were conﬁ  rmed in the reports of two patients 
with rtN236T, who had serum HBV DNA reductions of  4 
log10 copies/mL when switched from ADV to TDF therapy. 
TDF induces a rapid response also in patients with resistance 
or suboptimal response to ADV.11,45,46
Until now TDF resistance has been described in only two 
HIV/HBV coinfected patients, demonstrating the rtA194T 
mutation in addition to LAM resistance.20
In vitro studies on TDF susceptibility to the rtA194T 
mutation demonstrate conﬂ  icting results, so its clinical 
signiﬁ  cance needs to be determined. Also the two cases 
reported above do not represent the typical clinical pattern 
(CD4 count cells, HBV DNA levels, aminotransferase levels) 
seen in patients who develop antiviral-resistance mutations, 
and the surveillance for other TDF-resistance mutations 
should be continued.12,20
The most recent literature reports sporadic observations 
about rtI233V mutation and rtV214A and rtQ215S variants 
associated with suboptimal response to TDF monotherapy: 
further studies are needed to clarify the clinical signiﬁ  cance 
of these data.22,47
Overall, HBV resistance to TDF is infrequently found 
during the ﬁ  rst years on therapy, making it an attractive candi-
date for treatment of CHB. In a matched-controlled study no 
marked difference was found in antiviral efﬁ  cacy of treatment 
with TDF after the development of LAM resistance compared 
with the ﬁ  rst-line combination therapy of TDF plus LAM 
during a median follow-up of about 2 years: inhibition of 
HBV DNA, loss of HBeAg and loss of HBsAg did not differ 
between the two study groups. However, differences might 
be seen beyond a treatment period longer than 2 years.48
Although the authors matched for HBV DNA level at 
TDF initiation, this study was performed at non-comparative 
time-points, ie, pretreatment in the combination group and 
after the development of LAM resistance in the monotherapy 
group. To compare the efﬁ  cacy of the two strategies on HBV 
DNA suppression over time appropriately, matching should 
have been performed at baseline (pre-HBV therapy) in all 
patients.
Therefore Matthews and Dore suggest the importance of 
a new randomized clinical trial analyzing pre-therapy HBV 
DNA levels in the two groups.49
It has been observed in vitro that the use of antiviral 
drugs induces changes in antigenic sites of HBsAg; YMDD 
mutation may also provide a means for escape of HBV 
vaccine. Circulation of HBV encoding envelope mutations 
with diminished HBsAg–HBsAb binding, as a result of 
selection of drug-resistance mutations, may occur particularly 
in patients infected with HBV genotype A, the most prevalent 
genotype among HBV/HIV coinfected patients. Such 
mutations might represent a public health concern because of 
the potential risk of transmission of HBV drug- and vaccine-
resistant strains.50–52
Thus, TDF could potentially reduce transmission of resis-
tant HBV to both vaccinated and unvaccinated contacts.50
TDF and entecavir represent currently the only drugs that 
have demonstrated a very low rate of resistance and thus are 
preferred for monotherapy.5
Nevertheless the ﬁ  rst case of entecavir resistance in a 
LAM-resistant patient has already been described: entecavir 
was discontinued and treatment was switched to TDF, which 
resulted in a decline of HBV DNA below 1000 copies/mL. 
On the basis of therapy outcomes, TDF has proven to be a 
good treatment option for entecavir-resistant patients.53
The future management of CHB appears to be more 
promising than ever before, with many therapeutic options 
currently available, new drugs in development, and differ-
ent on-treatment strategies for optimizing the use of current 
agents undergoing investigation.5
Unfortunately, in the management of CHB, combination 
therapy with nucleos(t)ide analogs may be limited because 
they have essentially similar sites of actions, the HBV 
polymerase, which may make it difﬁ  cult to enhance antiviral 
efﬁ  cacy through additive on synergic effects.28Therapeutics and Clinical Risk Management 2009:5 183
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Treatment strategies should, however, be focused on 
preventing development of resistance by suppressing viral 
replication as quickly and completely as possible, rather 
than adjustment of therapy after the emergence of resistance, 
thereby limiting treatment options due to cross-resistance, and 
allowing for development of multi-resistant HBV variants.20
Adverse events
TDF is both safe and well tolerated. The most frequent 
adverse reactions in patients receiving TDF in clinical 
trials, which were not dose-related, were mild to moderate 
gastrointestinal events, as nausea, diarrhea, vomiting, and 
ﬂ  atulence.54,55
Laboratory abnormalities observed in these studies 
occurred with similar frequency in the TDF and placebo 
or active control groups, with the exception of lipid 
abnormalities, which were reported at higher frequencies in 
the control groups. In one study reduction in bone mineral 
density, but not incidence of bone fractures, was greater in 
the TDF group compared with the active control.55
In terms of nephrotoxicity, several case reports have been 
published on the occurrence of renal insufﬁ  ciency, tubular dys-
function, Fanconi’s syndrome, and diabetes insipidus in HBV/
HIV coinfected patients treated with TDF. In most instances, 
the renal problems resolved after TDF was discontinued 
and were observed in patients who were receiving multiple 
medications, some of which may be nephrotoxic or compete 
for renal tubular secretion of TDF.6,12,56
Nelson et al reported the results of a study on 10,343 
HIV-positive patients after 4 years of treatment with TDF to 
analyze its possible adverse effects. The incidence of any type 
of serious renal adverse events was 0.5%, similar to other data 
reported in smaller cohorts: elevations in serum creatinine at 
or above grade 1 or grade 2 were observed in 2.2% and 0.6% 
of patients, respectively; renal failure (acute and chronic) was 
reported in 0.3%. Other renal events, such as nephritis and 
proteinuria, occurred in  0.1%. As possible risk factors for 
renal adverse events, sepsis/serious infection (24%), history of 
renal disease/baseline renal impairment (24%), late stage HIV 
(22%), concurrent nephrotoxic drug (19%) and hypertension 
(16%) were observed.55
Other serious adverse events observed in the study of 
Nelson et al with an incidence  1%, included pancreatitis 
(0.3%), fever (0.1%), pneumonia (0.1%), lactic acidosis 
(0.1%), bone abnormalities ( 0.1%).55
Toxicity, as shown by peripheral neuropathy, lipodystrophy, 
lactic acidosis and pancreatitis, appears associated with 
mitochondrial dysfunction.10,55
Because TDF may cause nephrotoxic effects, periodic 
monitoring of renal function during nucleotide therapy is 
advisable,1,6,55 but we can conclude that this drug, alone, 
is characterized by a relative lack of nephrotoxicity and 
appears an optimal drug for post-transplantation HBV 
prophylaxis.57
TDF also showed in vitro an hematopoietic toxicity, 
compared with other antiviral molecules, superior only 
to LAM.58
TDF has been assessed for its safety and efﬁ  cacy in 
pregnant typo Rhesus monkeys. Efﬁ  cient placental transport 
of TDF and signiﬁ  cant reduction of viral load in simian 
immunodeﬁ  ciency virus (SIV)-infected fetuses were shown 
to result in healthy newborns, although the maternal dose 
used (30 mg/kg/day) throughout gestation transiently 
affected maternal bone biomarkers and altered some fetal 
parameters. Further studies are necessary to determine the 
long term effects.10
Conclusions
CHB is a largely diffuse infectious disease, so an efﬁ  cient 
and safe arsenal of medications is very important.
Among the nucleoside and nucleotide agents TDF may 
be preferable for ﬁ  rst-line therapy and also represents a 
milestone. However further studies are necessary to inves-
tigate the incidence of side effects, its efﬁ  cacy in the long 
term and to prove its potential availability in other clinical 
challenges.
We consider that in the near future HBV genome 
sequencing and phenotypic analysis, rather than empirical 
treatment, will critically inﬂ  uence clinical approach such as 
treatment choice, dosage and duration therapy.
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